Radiation for prostate cancer using smaller, targeted doses
Part of Cancer, Digestive system, Kidney & urinary clinical trials.
This trial studies a specific radiation schedule for prostate cancer (with an extra “boost” dose) and checks whether it works well and is tolerable. It may help people with higher-risk, localized prostate cancer by aiming at the cancer while limiting side effects to surrounding tissues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate adenocarcinoma (the most common type of prostate cancer).
- Your cancer is considered adverse intermediate risk or high localized risk based on scans, PSA, and biopsy results.
- Your estimated chance of lymph node involvement is above 15%, but you have no proven spread to lymph nodes in the pelvis (N0 or not assessable).
- Your prostate is smaller than 60 cubic centimeters on MRI/ultrasound, and there is no pelvic lymph node swelling (≥15 mm) on CT/MRI.
- You have no bone or organ metastases on CT and bone scan, and you started hormone therapy within the last 90 days (or you will start it right before radiation).
- Your urinary symptoms are mild (IPSS under 12) and you are not taking an alpha-blocker; you also have no prior pelvic radiation and can attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a newer, more precise radiation treatment that gives a higher dose to the main tumor while keeping radiation to the rest of the prostate the same. It is for men with intermediate- or high-risk prostate cancer who haven't had prior prostate radiation or removal.
This study tests a stronger, focused radiation plan for intermediate to higher-risk prostate cancer. It combines a high-dose internal radiation “boost” with external radiation to try to improve cancer control while keeping side effects manageable.
This trial tests a more concentrated radiation schedule for early-stage prostate cancer, using an extra high-dose “boost” delivered from inside the body. It may help by treating the prostate more precisely while aiming to keep side effects manageable.
This trial compares two types of radiation treatments for prostate cancer that has not spread to lymph nodes or other parts of the body. It tests whether adding a higher dose of radiation to the main tumor helps control the cancer better than standard radiation alone.
This trial tests whether giving higher radiation doses to the prostate and pelvic lymph nodes is more effective than treating only the prostate. You may benefit if your prostate cancer has spread to nearby lymph nodes but not to bones or other organs, and you are getting hormone therapy.
This trial studies how safe and effective different high-dose radiation levels are for prostate cancer placed directly in the prostate (HDR brachytherapy). It may help by finding a dose that controls the cancer while keeping side effects acceptable.
Hear when a new To Evaluate the Rate of Digestive and Urinary Toxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.